Tag: M.W=400-450

Yonezawa, Hidetoshi published the artcileDiscrepancy between the potency of various trypsin inhibitors to inhibit trypsin activity and the potency to release biologically active cholecystokinin-pancreozymin, Application of 2-(4-((4-Guanidinobenzoyl)oxy)phenyl)acetic acid methanesulfonic acid salt, the publication is Japanese Journal of Physiology (1984), 34(5), 849-56, database is CAplus and MEDLINE.

Injection of various trypsin??[9002-07-7] inhibitors into the lumen of the isolated perfused rat duodenum increased the amount of biol. active cholecystokinin-pancreozymin (CCK-BA) [9011-97-6] in the vascular perfusate. The potency to induce CCK-BA release of the various trypsin inhibitors diffeed. Injection of Et?p-(6-guanidinohexanoyloxy)benzoate?methanesulfonate (FOY-007) [56974-61-9] (100 ¦Ìmol); p-ethoxycarbamoylthio-6-guanidinocaproate phosphate (FOY-129) (110 ¦Ìmol); 4-(4-guanidinobenzoyloxy)phenylacetic?acid (FOY-251) [71079-09-9] (128 ¦Ìmol); N,N-dimethylcarbamoylmethyl-4-(4-guanidinobenoyloxy)phenylacetate?methanesulfonate (FOY-305) [59721-29-8] (80 ¦Ìmol); and p-aminobenzamidine-2HCl (p-ABA) [2498-50-2] (300 ¦Ìmol) caused release of CCK-BA amounting to 1042, 247, 252, 682, and 302 pM, resp. The potency to induce CCK-BA release was not correlated with the potency to inhibit trypsin activity. The present results do not support the hypothesis that a neg. feedback regulation of pancreatic enzyme secretion is exerted by intraluminal trypsin in the rat.

Japanese Journal of Physiology published new progress about 71079-09-9. 71079-09-9 belongs to catalysis-chemistry, auxiliary class Salt,Carboxylic acid,Carbamidine,Amine,Benzene,Ester,Protease,Ser/Thr Protease, name is 2-(4-((4-Guanidinobenzoyl)oxy)phenyl)acetic acid methanesulfonic acid salt, and the molecular formula is C14H10O4S2, Application of 2-(4-((4-Guanidinobenzoyl)oxy)phenyl)acetic acid methanesulfonic acid salt.

Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia

Paleologos, Evangelos K. published the artcileCationic surfactant-based polyfluorate salts: Phase separation and analytical applications in the extraction and preconcentration of ionic species prior to liquid chromatography, Application of N-hexadecyltrimethylammoniumhexafluorophosphate, the publication is Journal of Chromatography A (2005), 1066(1-2), 19-25, database is CAplus and MEDLINE.

The liquid-solid phase separation originating from the formation of cationic surfactant-based polyfluorate salts (CSBPS) has been explored for extracting and preconcg. ionic species. Two cationic surfactants were tested; one with aliphatic hydrocarbon tail [Cetyltrimethylammonium bromide (CTAB)]and the other containing a heterocyclic ring [Hexadecylpyridinium bromide (HPyBr)]. Phase separation possibility was investigated with the use of hexafluorophosphates (PF₆^–) and tetrafluoroborates (BF₄^–). The effect of added acid, base and salt on the phase separation and analyte extraction was also investigated. In all cases the obtained phase diagrams consisted of two regions: a homogeneous liquid region and a solid-liquid region. Analytes of hydrophilic and hydrophobic nature such as amines, amino acids and organic chromophores were used as test compounds in both their anionic and cationic forms. The resp. recoveries ranged from over 90% for anionic species and in the proximity of 50% for cationic species, remaining below 20% for neutral species. Extracts from alk. aqueous and plasma samples spiked with tyrosine and phenylalanine were also subjected to HPLC separation with UV detection with satisfactory results. On line application was also enabled using a flow through-solid phase extraction-HPLC hyphenated apparatus, thus adding the element of automatization and increased reproducibility.

Journal of Chromatography A published new progress about 101079-29-2. 101079-29-2 belongs to catalysis-chemistry, auxiliary class Surfactants, name is N-hexadecyltrimethylammoniumhexafluorophosphate, and the molecular formula is C19H42F6NP, Application of N-hexadecyltrimethylammoniumhexafluorophosphate.

Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia

Eynde, Jean Jacques Vanden published the artcileCOVID-19: failure of the DisCoVeRy clinical trial, and now-new hopes?, COA of Formula: C17H19N3O7S, the publication is Pharmaceuticals (2021), 14(7), 664, database is CAplus and MEDLINE.

The DisCoVeRy clin. trial aimed at the evaluation of four treatments for patients suffering from severe to critical COVID-19: Hydroxychloroquine, eventually associated with azithromycin; the combination lopinavir/ritonavir; the combination with the addition of interferon ¦Â-1a; remdesivir. The trial was discontinued due to the lack of pos. results. Meanwhile, many other potential options have been considered either to target the virus itself, the interactions with the host cells, or the cytokine storm frequently observed during the infection. Several of those options are briefly reviewed. They include vaccines, small mols., antibodies, and stem cells.

Pharmaceuticals published new progress about 71079-09-9. 71079-09-9 belongs to catalysis-chemistry, auxiliary class Salt,Carboxylic acid,Carbamidine,Amine,Benzene,Ester,Protease,Ser/Thr Protease, name is 2-(4-((4-Guanidinobenzoyl)oxy)phenyl)acetic acid methanesulfonic acid salt, and the molecular formula is C17H19N3O7S, COA of Formula: C17H19N3O7S.

Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia

Matsushima, Masashi published the artcileInhibition of enteropeptidase by antitrypsin drugs, Safety of 2-(4-((4-Guanidinobenzoyl)oxy)phenyl)acetic acid methanesulfonic acid salt, the publication is Biomedical Research (2001), 22(5), 257-260, database is CAplus.

We have investigated the inhibitory effects on porcine enteropeptidase of some typical synthetic amidino- and guanidino-compounds developed as antitrypsin drugs. The results indicated that enteropeptidase is inhibited by these compounds almost as strongly as trypsin; their IC₅₀ values were in the range of 0.008-4 ¦ÌM, which were much lower than that of the well-known trypsin/enteropeptidase inhibitor benzamidine.

Biomedical Research published new progress about 71079-09-9. 71079-09-9 belongs to catalysis-chemistry, auxiliary class Salt,Carboxylic acid,Carbamidine,Amine,Benzene,Ester,Protease,Ser/Thr Protease, name is 2-(4-((4-Guanidinobenzoyl)oxy)phenyl)acetic acid methanesulfonic acid salt, and the molecular formula is C17H19N3O7S, Safety of 2-(4-((4-Guanidinobenzoyl)oxy)phenyl)acetic acid methanesulfonic acid salt.

Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia

Beckh, Karlheinz published the artcileHepatic and pancreatic metabolism and biliary excretion of the protease inhibitor camostat mesilate, Computed Properties of 71079-09-9, the publication is International Journal of Pancreatology (1991), 10(3-4), 197-205, database is CAplus and MEDLINE.

The hepatic metabolism and biliary and pancreatic excretion of the serine protease inhibitor camostat mesilate and its metabolites FOY-251 and GBA were studied in rats in vivo and in situ liver-perfusion experiments After oral feeding (100 mg/kg) and i.v. infusion (5 mg/kg.h) of camostat mesilate, the original compound and both metabolites appeared in bile, but could not be detected in pancreatic juice. In plasma, only FOY-251 and GBA were detected. In the perfused rat liver, camostat mesilate (10 ¦ÌM) was eliminated by 33.8% and its molar rate of degradation to FOY-251 was 25.1%. During the study period about 0.1% of camostat mesilate and FOY-251 appeared in bile. The liver perfusion of FOY-251 or GBA revealed very low hepatic extraction rates of 10.3 and 2.4%, resp. In conclusion, the low hepatic extraction rate of camostat mesilate and its metabolites leads to high concentrations of the active metabolite FOY-251 in plasma. Camostat mesilate and its metabolites are effectively excreted into bile, but not in rat pancreatic juice.

International Journal of Pancreatology published new progress about 71079-09-9. 71079-09-9 belongs to catalysis-chemistry, auxiliary class Salt,Carboxylic acid,Carbamidine,Amine,Benzene,Ester,Protease,Ser/Thr Protease, name is 2-(4-((4-Guanidinobenzoyl)oxy)phenyl)acetic acid methanesulfonic acid salt, and the molecular formula is C17H19N3O7S, Computed Properties of 71079-09-9.

Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia

Xiao, Wu-Yi published the artcileClick Reaction-Assisted Peptide Immune Checkpoint Blockade for Solid Tumor Treatment, Name: Dbco-maleimide, the publication is ACS Applied Materials & Interfaces (2020), 12(36), 40042-40051, database is CAplus and MEDLINE.

One of the major challenges of immune checkpoint blockade (ICB) is the poor penetration of antibody for solid tumor treatment. Herein, peptides with deeper penetration capability are used to develop a click reaction-assisted peptide immune checkpoint blockade (CRICB) strategy that could in situ construct assemblies, enabling enhanced accumulation and prolonged PD-L1 occupancy, ultimately realizing high-performance tumor inhibition. First, the free DBCO-modified targeting peptide (TP) efficiently recognizes and binds PD-L1 in a deep solid tumor. Upon a reagent-free click reaction with a subsequently introduced azide-tethered assembled peptide (AP), the click reaction results in spontaneous self-aggregation in situ with enhanced accumulation and prolonged occupancy. In addition, the penetration of TP-AP (121.2 ¡À 15.5¦Ìm) is significantly enhanced compared with that of an antibody (19.9 ¡À 5.6¦Ìm) in a solid tumor tissue. More importantly, significant immunotherapy effects and negligible side effects are observed in 4T1 and CT26 tumor-bearing mice models treated with TP-AP, suggesting the high-performance tumor inhibition attributed to the CRICB strategy. In summary, this CRICB strategy manifest the preferable effects of immune checkpoint blockade, thereby extending the biomedical application of assembling peptides.

ACS Applied Materials & Interfaces published new progress about 1395786-30-7. 1395786-30-7 belongs to catalysis-chemistry, auxiliary class Inhibitor, name is Dbco-maleimide, and the molecular formula is C18H26ClN3O, Name: Dbco-maleimide.

Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia

Henning, Ryan K. published the artcileDegradation of Akt using protein-catalyzed capture agents, Safety of Dbco-maleimide, the publication is Journal of Peptide Science (2016), 22(4), 196-200, database is CAplus and MEDLINE.

Abnormal signaling of the protein kinase Akt has been shown to contribute to human diseases such as diabetes and cancer, but Akt has proven to be a challenging target for drugging. Using iterative in situ click chem., we recently developed multiple protein-catalyzed capture (PCC) agents that allosterically modulate Akt enzymic activity in a protein-based assay. Here, we utilize similar PCCs to exploit endogenous protein degradation pathways. We use the modularity of the anti-Akt PCCs to prepare proteolysis targeting chimeric mols. that are shown to promote the rapid degradation of Akt in live cancer cells. These novel proteolysis targeting chimeric mols. demonstrate that the epitope targeting selectivity of PCCs can be coupled with non-traditional drugging moieties to inhibit challenging targets.

Journal of Peptide Science published new progress about 1395786-30-7. 1395786-30-7 belongs to catalysis-chemistry, auxiliary class Inhibitor, name is Dbco-maleimide, and the molecular formula is C25H21N3O4, Safety of Dbco-maleimide.

Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia

Masuya, Takahiro published the artcilePinpoint Dual Chemical Cross-Linking Explores the Structural Dynamics of the Ubiquinone Reaction Site in Mitochondrial Complex I, Recommanded Product: Dbco-maleimide, the publication is Biochemistry (2021), 60(10), 813-824, database is CAplus and MEDLINE.

The ubiquinone reduction step in NADH-ubiquinone oxidoreductase (complex I) is the key to triggering proton translocation in its membrane part. Although the existence of a long and narrow quinone-access channel was identified, it remains debatable whether the channel model can account for binding of various ligands (ubiquinones and inhibitors) to the enzyme. The authors previously proposed that the matrix-side interfacial region of the 49 kDa, ND1, PSST, and 39 kDa subunits, which is covered by a loop connecting transmembrane helixes (TMHs) 1 and 2 of ND3, may be the area for entry of some bulky ligands into the quinone reaction cavity. However, this proposition lacks direct evidence that the cavity is accessible from the putative matrix-side region, which allows ligands to pass. To address this, the authors examined whether Cys³⁹ of ND3 and Asp¹⁶⁰ of 49 kDa can be specifically crosslinked by bifunctional crosslinkers (tetrazine-maleimide hybrid, named TMBC). On the basis of the structural models of complex I, such dual crosslinking is unexpected because ND3 Cys³⁹ and 49 kDa Asp¹⁶⁰ are located on the TMH1-2 loop and deep inside the channel, resp., and hence, they are phys. separated by peptide chains forming the channel wall. However, three TMBCs with different spacer lengths did crosslink the two residues, giving new crosslinked ND3/49 kDa subunits. Chem. modification of either ND3 Cys³⁹ or 49 kDa Asp¹⁶⁰ blocked the dual crosslinking, ensuring the specificity of the crosslinking. Altogether, this study provides direct evidence that the quinone reaction cavity is indeed accessible from the proposed matrix-side region covered by the ND3 TMH1-2 loop.

Biochemistry published new progress about 1395786-30-7. 1395786-30-7 belongs to catalysis-chemistry, auxiliary class Inhibitor, name is Dbco-maleimide, and the molecular formula is C25H21N3O4, Recommanded Product: Dbco-maleimide.

Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia

Yao, Xiyuan published the artcileCysteine-Directed Bioconjugation of a Platinum(II)-Acridine Anticancer Agent, HPLC of Formula: 1395786-30-7, the publication is Inorganic Chemistry (2019), 58(1), 43-46, database is CAplus and MEDLINE.

Classical maleimide Michael addition chem. in conjunction with copper-free click chem. was investigated as a synthetic strategy to attach cytotoxic platinum-acridine hybrid agents to carrier proteins. The structural integrity and selectivity of the model payloads, which were validated in human serum albumin (HSA) using mass spectrometric anal. and heteronuclear 2D ¹H-¹⁵N HSQC NMR experiments, may have broad utility for the targeted delivery of highly cytotoxic platinum acridines and other nonclassical platinum containing anticancer agents.

Inorganic Chemistry published new progress about 1395786-30-7. 1395786-30-7 belongs to catalysis-chemistry, auxiliary class Inhibitor, name is Dbco-maleimide, and the molecular formula is C2H2N4O2, HPLC of Formula: 1395786-30-7.

Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia

Otsuki, Makoto published the artcileBeneficial effects of the synthetic trypsin inhibitor camostate in cerulein-induced acute pancreatitis in rats, COA of Formula: C17H19N3O7S, the publication is Digestive Diseases and Sciences (1990), 35(2), 242-50, database is CAplus and MEDLINE.

The therapeutic effect and the mechanism of action of the synthetic trypsin inhibitor camostate were studied in a rat model of acute interstitial pancreatitis induced by caerulein. Rats with acute pancreatitis were given either 100 mg/kg body weight camostate or water via an orogastric tube 30 min after the caerulein injection. The elevation of serum amylase activity was reduced by camostate treatment and the peak value was seen 1 h earlier than that observed in the control group. Camostate also inhibited the reduction in pancreatic content of lipase and amylase seen during exptl. pancreatitis. These effects were accompanied by alleviation of the histol. signs of acute pancreatitis such as cellular infiltration and acinar cell vacuolization. After oral administration, camostate and its metabolite were absorbed from the intestine and were detectable in plasma for >6 h in concentrations high enough to have antiprotease activity. In addition, camostate in the duodenum was able to increase pancreatic juice flow and protein output and to stimulate endogenous secretin release. Thus, oral administration of camostate reduces the severity of caerulein-induced acute pancreatitis by releasing endogenous secretin and by its antiprotease activity.

Digestive Diseases and Sciences published new progress about 71079-09-9. 71079-09-9 belongs to catalysis-chemistry, auxiliary class Salt,Carboxylic acid,Carbamidine,Amine,Benzene,Ester,Protease,Ser/Thr Protease, name is 2-(4-((4-Guanidinobenzoyl)oxy)phenyl)acetic acid methanesulfonic acid salt, and the molecular formula is C17H19N3O7S, COA of Formula: C17H19N3O7S.

Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia